Evaluation shows improved oral bioavailability for acalabrutinib using polymer-lipid hybrid nanoparticles, suggesting implications for therapeutic effectiveness.
Acalabrutinib loaded polymer lipid hybrid nanoparticles, developed and optimized using a DoE approach, were able to improve the oral bioavalability of the molecule. This highlights the potential of the PLHN technology to improve therapeutic performance of acalabrutinib.
No takes yet. Share an insight, caveat, or question.
Sinha et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: